Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 16 of 53 for:    Orange B

Effect of a Nitric Oxide Supplementation Product on Endothelial Dysfunction and Prehypertensive Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03895749
Recruitment Status : Completed
First Posted : March 29, 2019
Last Update Posted : March 29, 2019
Sponsor:
Collaborator:
Neogenis Laboratories
Information provided by (Responsible Party):
Hypertension Institute, Nashville

Brief Summary:
The nitric oxide supplementation product, Neo40 Daily®, provides a dietary source of No2-. The product also allows for robust No2-reduction to NO from the extremely potent nitrite-reducing capacity of the polyphenols found in Hawthorne berry.(Bartsch et al., 1993) Neo40 Daily® is a unique product since it provides the dietary source of No2-, as well as the rate limiting No2- reduction activity.

Condition or disease Intervention/treatment Phase
Hypertension Dietary Supplement: NEO40 Daily Not Applicable

Detailed Description:
Neo40 Daily® facilitates both endothelial dependent and independent NO production. The acute effects of Neo40 Daily® have been demonstrated in hypertensive patients.(Zand et al., 2011) Within 30 minutes following a single dose of the Neo40 Daily®, a significant reduction in systolic/diastolic BP and vascular compliance was observed, as well as, 4 hours following treatment, a significant improvement in endothelial function was seen. Furthermore, it has been used in longer term clinical trials to show elevated plasma levels of No3• and No2·, indicating an increase in systemically available NO, and lower levels of triglycerides in an older population with cardiovascular risk factors.(Zand et al., 2011) This pilot study also demonstrated a trend towards reduced BP and improved quality of life among its prehypertensive participates (Biswas et al., 2015). This current clinical trial aims to expand on this pilot study and examine the effect of NO supplementation on a pre- and mildly hypertensive populations with endothelial dysfunction as measured by EndoPAr® and asymmetric dimethyl L-arginine (ADMA). In a double blinded placebo controlled parallel arm study, we will further investigate the effect of Neo40 Daily® on 40 pre- and mildly hypertensive subjects with regards to changes in blood pressure, endothelial dysfunction and other markers of NO availability and CVD risk.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 42 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Phase II, randomized,double-blind, placebo-controlled 2 arm parallel
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: placebo-controlled study material
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo-Controlled Parallel Study to Investigate the Effect of a Nitric Oxide Supplementation Product on Endothelial Dysfunction and Prehypertensive Adults
Actual Study Start Date : April 5, 2017
Actual Primary Completion Date : February 1, 2018
Actual Study Completion Date : April 18, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Neo40 Daily
Per Capsule: N5-carbamoylornithine 100 mg, crataegus laevigata 100 mg, L-ascorbic acid 50 mg, vitamin B-12 0.05 mg, vitamin C 50 mg.
Dietary Supplement: NEO40 Daily
Per Capsule: N5-carbamoylornithine 100 mg, crataegus laevigata 100 mg, L-ascorbic acid 50 mg, vitamin B-12 0.05 mg, vitamin C 50 mg.

Placebo Comparator: Placebo
Per Capsule: Beet Juice concentrate, Carmine, Croscarmellose Sodium, D-Mannitol, Magnesium Stearate, Orange flavour, Silicon dioxide, Stevia rebaudiana leaf, Xylitol.
Dietary Supplement: NEO40 Daily
Per Capsule: N5-carbamoylornithine 100 mg, crataegus laevigata 100 mg, L-ascorbic acid 50 mg, vitamin B-12 0.05 mg, vitamin C 50 mg.




Primary Outcome Measures :
  1. The primary efficacy outcome is the between-group changes from baseline (Day 0) to end of study (Day 30) in daytime mean systolic and diastolic BP. [ Time Frame: 30 days ]
    The primary efficacy outcome to be analyzed is the between-group changes from baseline (Day 0) to end of study (Day 30) in daytime mean systolic and diastolic BP readings using AHA guidelines.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects with seated resting systolic blood pressures between 130-160 mmHg and diastolic between 85 and 100 mm Hg (inclusive) at screening visit
  • Subjects with an elevated ADMA
  • Agreement to maintain current level of physical activity and diet throughout the study
  • Agrees to comply with study procedures including willingness to fast at least 12 hours before blood samples, abstain from alcohol two days prior to blood sampling and blood pressure measurement, abstain from coffee at least 14 hours before blood pressure

Exclusion Criteria:

  • Females who are pregnant, breastfeeding or planning to become pregnant during the course of the study.
  • Seated office systolic blood pressure ou side of the target range (systolic BP<130 mm Hg or >160 mmHg) or diastolic BP< 85 or 100 mm Hg at screening visit
  • The use of natural health products for th treatment of hypertension within 2 weeks of screening
  • Significant cardiac history defined as a h story of myocardial infarction (Ml); coronary angioplasty or bypass graft(s); Valvular isease or repair; unstable angina pectoris; transient ischemic attack (TIA); cerebrovascular accidents (CVA); congestive heart failure; or coronary artery disease (CAD)
  • Type I diabetes
  • Unstable medical conditions that in the opinion of the Principle Investigator preclude the subject from participating in the study
  • Alcohol or drug abuse within the last 6 months
  • Clinically significant abnormal laboratory results at screening
  • Participation in a clinical research trial wi hin 30 days prior to randomization
  • Allergy or sensitivity to study supplemen ingredients
  • Individuals who are cognitively impaired nd/or who are unable to give informed consent
  • Any other condition which in the lnvestig tor's opinion may adversely affect the subject's ability to complete the study or its meas res or which may pose significant risk to the subject.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03895749


Locations
Layout table for location information
United States, Tennessee
Hypertension Institute
Nashville, Tennessee, United States, 37205
Sponsors and Collaborators
Hypertension Institute, Nashville
Neogenis Laboratories

Layout table for additonal information
Responsible Party: Hypertension Institute, Nashville
ClinicalTrials.gov Identifier: NCT03895749     History of Changes
Other Study ID Numbers: Neo40 ADMA
First Posted: March 29, 2019    Key Record Dates
Last Update Posted: March 29, 2019
Last Verified: March 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Nitric Oxide
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Free Radical Scavengers
Antioxidants
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Endothelium-Dependent Relaxing Factors
Vasodilator Agents
Gasotransmitters
Protective Agents